Chronic dementing conditions, genomics, and new opportunities for nursing interventions
- PMID: 17181080
- DOI: 10.1111/j.1547-5069.2006.00123.x
Chronic dementing conditions, genomics, and new opportunities for nursing interventions
Abstract
Purpose: To (a) provide an overview of chronic dementing conditions; (b) discuss the etiologic and clinical characteristics of Alzheimer disease (AD) and Parkinson disease (PD) within the framework of the family systems genetic illness model; and (c) to explore opportunities to enhance outcomes through the integration of genomics information and technologies into nursing practice.
Design: An integrated review of the literature, including the organizing construct of the family systems genetic illness model.
Findings: AD and PD are both influenced by genetic and environmental factors; in a small percentage of families, gene mutations are the primary etiologic factor. Genetic testing is an option for some families experiencing early-onset, familial disease. Presymptomatic and diagnostic genetic testing have limited clinical utility for the more common late-onset AD and PD.
Conclusions: The current abilities of healthcare professionals to effectively intervene in people with AD and PD are limited by an incomplete understanding of the biologic basis of these diseases. Advances in genomics research and technology are providing the information and tools necessary to understand the molecular basis of these devastating disorders toward the goal of more specific and effective interventions.
Similar articles
-
The evolving role of genomics in shaping care for persons with dementia.Nurs Clin North Am. 2004 Sep;39(3):581-92. doi: 10.1016/j.cnur.2004.02.012. Nurs Clin North Am. 2004. PMID: 15331303 Review.
-
The role of NAT2 gene polymorphism in aetiology of the most frequent neurodegenerative diseases with dementia.Neurol Neurochir Pol. 2007 Sep-Oct;41(5):388-94. Neurol Neurochir Pol. 2007. PMID: 18033638
-
CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.Neurol Neurochir Pol. 2007 Mar-Apr;41(2):113-21. Neurol Neurochir Pol. 2007. PMID: 17530572 Clinical Trial.
-
Unraveling the biological mechanisms in Alzheimer's disease--lessons from genomics.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):340-7. doi: 10.1016/j.pnpbp.2010.12.019. Epub 2010 Dec 27. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21193006 Review.
-
TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.Neurodegener Dis. 2005;2(1):28-35. doi: 10.1159/000086428. Neurodegener Dis. 2005. PMID: 16909000
Cited by
-
Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease.Genet Med. 2010 Apr;12(4 Suppl):S71-82. doi: 10.1097/GIM.0b013e3181d5a68e. Genet Med. 2010. PMID: 20393312 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical